Business Wire·Nov 9, 2026, 7:00 AM ET

Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa

Zura Bio Limited's Phase 2 TibuSHIELD trial for tibulizumab in moderate-to-severe hidradenitis suppurativa failed to meet its primary endpoint of percentage change from baseline in total abscess and inflammatory nodule count at Week 16.
Key secondary endpoints including HiSCR50 and HiSCR75 response rates were not met across both 300 mg and 150 mg treatment arms.
Although tibulizumab arms showed slightly higher percentage reductions in abscess and nodule counts compared to placebo, the differences were not statistically significant enough to meet efficacy criteria.
Zura is discontinuing the development of tibulizumab for hidradenitis suppurativa due to these results.
Both tibulizumab doses were well tolerated, with safety profiles consistent with established IL-17 and BAFF inhibition, including one death unrelated to treatment and one case of inflammatory bowel disease exacerbation.
The ongoing TibuSURE trial in systemic sclerosis will continue, with topline data expected in the first half of 2027.
The planned NEXUS-PMR trial in polymyalgia rheumatica will proceed, with data anticipated in the fourth quarter of 2028.
Additional analyses regarding pharmacokinetics, exposure-response relationships, and HS-specific factors are ongoing to understand the biological implications of the trial results.
Zura maintains sufficient cash and cash equivalents of $187.7 million as of September 30, 2026, to support operations through at least the end of 2028.